End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,004 INR | +1.00% | -0.81% | +1.25% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.33 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.25% | 2.02B | - | ||
+14.70% | 64.97B | A- | ||
-1.61% | 47.76B | A- | ||
+14.58% | 40.72B | B+ | ||
+20.84% | 26.88B | A- | ||
+9.54% | 19.29B | C+ | ||
+1.16% | 17.53B | B+ | ||
-21.87% | 16.03B | A- | ||
+1.11% | 15.17B | B+ | ||
-11.34% | 15.06B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- VINATIORGA Stock
- VINATIORGA Stock
- Ratings Vinati Organics Limited